Diabetes is a huge and growing healthcare worry, especially in Western countries. The treatment of both types - 1 and 2 - of this disease has changed radically over the past few years. This work provides an overview of all the changes that will come to be implemented in clinical practice. Summarizing all aspects of treatment, this book delineates the large amount of research work that has been completed over the last few years into the relief of complications in diabetes and vascular medicine in general.

Paget's disease is an old disease historically, but a new disease therapeutic ally. Human remains unearthed in Lancashire, England, dating from ap proximately 900 AD, show clear evidence of the aftliction. However, it was not until the 1800s that physicians rediscovered the condition, and a little more than 100 years ago that Sir James Paget published a perceptive and accurate description of the disease from the clinical and pathologic points of view. He felt the disease represented an inflammatory condition of the skeleton and hence named it osteitis deformans. The condition again lapsed into anonymity for several decades afterwards, and therapeutic approaches did not evolve until after World War II when several groups, located mainly in the Boston area, began using a variety of agents, includ ing corticosteroids for treatment of this condition. These early attempts at therapy were unsuccessful and the condition remained essentially untreat able until the development of the calcitonins and the bisphosphonates in the 1970s. In 1978, the Paget's Disease Foundation, a private nonprofit volun tary health agency, was founded to assist individuals aftlicted by Paget's disease of bone, to provide education regarding this condition to the medical community, and to encourage research efforts to better under stand and treat the condition. An international conference was organized under the aegis of the Paget's Disease Foundation and was held in New York City in October, 1989, ten years after the founding of the Paget's Disease Foundation."

The aim of this volume is to underline that promoting physical activity is crucial to preventing illness and maintaining our health, thus leading to a reduction in healthcare costs. Over the last decade studies have shown that physical exercise plays an important role in maintaining an individual's psycho-physical balance. Physical activity therefore helps in tackling today's major health challenges, including diabetes, high blood pressure, and cardiorespiratory diseases.

The cover of this book summarizes the central features of the sequestration hypothesis: Commonplace appearances seen in human coronary artery, fat stained in paraffin seetions by a new technique explained in Chapter Eleven, are arranged to suggest pathways of evolution toward atheroma. The hypothesis formulated and defended in the pages ofthis book is this: Fibroplasia progresses upward in column "a" from "la" to "3a" as a characteristic feature of aging. This starts sooner and progresses faster in men than in wornen. Numbers ofSMC's remain essentially constant so that fibroplasia per SMC steadily increases. The rise upward conveys an increasing propensity to sequester atherogenic lipids, causing transition rightward into column "b." Sequestered extracellular lipid then attracts fatty streak elements, especially foam cells and lyrnphocytes, to propel the arterial site rightward into column "c." Frame "lc" corresponds to the AHA Lesions Committee classification type IIb, the progression resistant fatty streak arising directly without prior lipid sequestration; this can progress to atheroma, but slowly after much delay, although extreme provocation can accelerate the process. Such progression is rightward toward atherorna with thin cap, not upward toward fibroplastic thickening. Frame "2c" corresponds to the AHA classification, type Ha, progression prone fatty streaks. These readily evolve into atheroma, again by horizontal progression.

This timely book provides an overview of topics related to obesity. These include associated health risks, childhood obesity, genetics, evaluation, treatment, behavioral strategies, and successes and failures in preventing obesity. The volume covers evaluation guidelines, different approaches to treatment, including diet, exercise, behavior, drugs, and surgery to deal with the current world-wide obesity epidemic.

Only comprehensive reference book on pressure ulcers and their management

Only book in its field endorsed by the European Pressure Ulcer Advisory Panel, the leading European authority on pressure ulcers

Research into the paraoxonase (PON) multigene family has really only blossomed in the last 10 years. Before this time only PON1 was known and research was restricted to toxicologists investigating the metabolism of organophosphate insecticides and nerve gases and a few mad scientists searching for natural substrates.

Since this time two new members PON2 and PON3 have been discovered, all 3 PONs have been shown to act as antioxidants and the PON family has taken centre stage as major players in the development of a wide variety of diseases such as cardiovascular disease, diabetes mellitus, rheumatism, Alzheimer and many more while remaining important in determining organophosphate toxicity.

In September 2006 the 2nd International Conference on Paraoxonases took place in Hajduszoboszlo, Hungary, bringing together the world's foremost experts in the field. The current book is a distillation of the plenary lectures which took place at the meeting, resulting in a comprehensive up to date, state of the art review of current paraoxonase research."

With the advent of the worldwide obesity epidemic, a concurrent rise has occurred in the prevalence of type 2 diabetes mellitus and metabolic syndrome. Type 2 diabetes mellitus is affecting younger individuals-the disease is no longer exclusive to adulthood. Diabetic micro- and macrovascular complications are also occurring at an earlier age, leading to increasing demands and costs on the healthcare system. In addition, the morbidity, disability and premature death caused by diabetic complications create a huge burden to families, employers and society at large. Thankfully, there has been a tremendous growth in new therapeutic classes of medications to help manage type 2 diabetes mellitus. These agents target many of the pathophysiologic defects of the disease with fewer side effects than the older agents. Newer insulin formulations have more predictable kinetics so patients can achieve better glycemic control with less risk of hypoglycemia and weight gain. Insulin delivery devices have also improved to include higher quality insulin pens, finer and shorter pen needles, and more technologically advanced insulin pumps. As part of the Oxford American Endocrinology Library series, this handbook reviews the epidemiology and pathophysiology of obesity and type 2 diabetes mellitus. The content covers micro- and macrovascular diabetic complications, the array of glucose regulating therapies, treatment algorithms targeting the pathophysiologic defects of type 2 diabetes mellitus as well as strategies for macrovascular risk reduction via therapeutic lifestyle change (diet, exercise, smoking cessation), pharmacotherapeutic treatment of dyslipidemia and hypertension, bariatric surgery and subcutaneous insulin infusion therapy, among other topics. Because of the concise yet comprehensive nature of the handbook, this volume is an excellent point-of-care reference for the clinician who regulary treats obese and diabetic patients.

Cardiovascular disease is a common cause of morbidity and mortality in people with diabetes, and it is an issue that is becoming increasingly important to both cardiologists and specialists in diabetes. The routine management of patients with diabetes now includes close attention to the methods to control hyperglycaemia that give maximum reduction in cardiovascular events. This pocketbook details the complications that diabetes presents in relation to heart disease, introduces the reader to various risk factors and discusses the possible treatments that can be explored. This second edition has also been updated throughout to include new trial data, new drugs and updates on treatment of diabetes in heart failure patients. The information in this book is presented in an easy to use format, and supplemented with key figures, tables and summarized research findings.

This book provides comprehensive coverage of the three most important themes in the field of Endocrine Disrupting Chemicals (EDC) research: the basic biology of EDCs, particularly their effects on reproductive systems; EDC effects on humans and wildlife, including biomedical considerations; and potential interventions and practical advice for dealing with the problem of EDCs.

Diabetes is now reaching epidemic proportions, and the associated complications of this disease can be disabling and even life-threatening. In Type 2 Diabetes: Methods and Protocols, leading investigators provide up-to-date explanations of commonly used laboratory protocols used in diabetes research. Covering the commonly described in vivo and in vitro model systems, the volume ultimately leads to an overall view of how cellular dysfunction and degeneration leads to susceptibility and diabetes disease progression. Written in the highly successful Methods in Molecular Biology series format, chapters include brief introductions to their respective subjects, lists of the necessary materials and reagents, step-by-step, readily reproducible protocols, and expert notes on troubleshooting and avoiding known pitfalls.

Comprehensive and cutting-edge, Type 2 Diabetes: Methods and Protocols offers succinct, proven techniques to aid research scientists and clinicians in continuing the study of this debilitating disease."

In this practical book, the authors of each chapter have synthesized the currently available evidence regarding specific issues in diabetes care. The chapters have been written by an interdisciplinary team of scientists and medical professionals. Such an approach emphasizes the need for collaboration in the care of any individual with diabetes and in the effort to find new therapies for the disease. This reference provides practical guidance in a single resource.

A. CORBIN Investigations on LHRH and its analogs have just completed their first decade. We have witnessed a veritable explosion of chemical, physiologic and pharmacologic data on this hypothalamic peptide and the approximately 1500 agonist and antagonist analogs that have been synthesized. In order to track this expanding field, I was asked to organize an international symposium on basic and clinical aspects of LHRH analogs as part of the Reproductive Health Care: CDS Symposium held in Maui, Hawaii, in October 1982. This meeting brought together a number of the leading investigators in the field. Much new state-of-the-art information was presented which I and my colleagues felt deserved a wider audience. Drs Vickery, Nestor, and Hafez consented to undertake this task. Upon review of the literature, it was apparent that there was no recent text which fully covered the breadth of developments in the field. Accordingly, the editors decided to use the symposium as a nucleus on which to build a singular, comprehensive state-of-the-art analysis of this rapidly growing discipline, and the application of such knowledge to reproductive medicine. As exemplified by the various areas of expertise provided by the individual contributors, it becomes obvious that the scope of the subject matter, while relating solely to a well-defined chemical class (LHRH analogs) and a circumscribed physiologic and pharmacologic entity (reproduction), has expanded enormously.

A lot of time has been spent trying to convince health care providers and policy makers of the enormous importance of macrovascular disease in persons with type 2 diabetes. In this volume, we present facts that dem onstrate how important it is to recognize macrovascular disease in these patients in daily practice. This volume has been compiled to help those already involved in dia betes care, to be more involved in cardiovascular risk control, a task that is not easily achieved. The area of cardiovascular risk in type 2 diabetes is heterogeneous. Trying to characterize it, we can only say: certainly we know more than we do, but for sure we do less than we could. Our challenge is to change this. Nicolae Htmcu Professor N. Hancu was born in Romania in 1940. He studied medicine at the Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, and obtained his speciality in internal medicine in 1970, and in diabetes, nutrition and metabolic disease in 1986. He was appointed Professor and Head of the Department of Diabetes, Nutrition and Metabolic Diseases of the same university in 1993. He has been a full member of the Romanian Academy of Medical Sciences since 1995. Professor Hancu's major interest is related to clinical lipidology, visceral obesity, and cardiovascular risk in type 2 diabetes. He has published over 200 papers and 14 books in this area. He has been invited as Visiting Professor at many universities in Madrid, Valladolid, Barcelona, and Los Angeles.

A concise survey by physicians and researchers of the latest thinking about the causes of diabetes and the best approaches to treating its acute and chronic complications. The authors pay special attention to explaining the molecular basis of diabetes and its complications, as well as to the many recent developments in whole pancreas and islet cell transplantation, including the means for avoiding the rejection of transplanted islets.

Even a brief scan of the table of contents of the present volume is enough to disclose the diversity of research interests and opinions in the field of lipidology. It is precisely this diversity that is the strength of our field and that was showcased by the XII International Symposium of DRUGS AFFECTING LIPID METABOLISM (DALM). The papers published here from these proceedings may be divided into three categories: those that define-and refine---our understanding ofthe clinical benefit of aggressive lipid management, those that develop our knowledge of ris!. assessment, and those that discuss the genetic, bio~hemical, and biophysical mechanisms underlying the pathology of coronary heart disease. On the clinical front, further analysis of the results of the Scandinavian Simvastatin Survival Study (4S) has indicated the cost-effectiveness of therapy in patients with established coronary heart disease. The West of Scotland Coronary Prevention Study (WOSCOPS), whose methodology was described at the DALM XII symposium, has demonstrated in a mostly primary-prevention population what 4S demonstrated for secondary prevention the year before: aggressive lipid-regulating therapy reduces coronary heart disease morbidity and mortality rates without concurrently increasing mortality from noncardiovascular causes. In the future, important considerations will be to develop protocols that maximize benefit in groups underrepresented in traditional clinical research for example, women and the elderly-and to improve compliance to existing treatment regimens. Furthermore, antioxidant, omega-3 fatty acid, and gene therapies warrant further investigation.

At a time of dramatic increases in the prevalence of obesity, it is appropriate that Type 2 diabetes has received a great deal of attention by the endocrinology community. Clearly, the management of insulin resistance and cardiovascular risk is a critical issue. However, it is important to also acknowledge and address Type 1 diabetes, whose prevalence is also increasing, and whose management remains complex. Currently it is estimated that 10-15% of those with diabetes carry the diagnosis of Type 1 diabetes, and frequently the diagnosis is not straightforward, as many clinicians recognize that more adults previously thought to have Type 2 diabetes actually have late-onset Type 1 diabetes (also termed latent autoimmune diabetes of the adult or LADA). Over the last decade tools for the management of Type 1 diabetes have also evolved; therefore, clinicians now have the opportunity to more closely replicate normal physiologic insulin secretion with either basal-bolus insulin therapy or continuous subcutaneous insulin infusions. While these advancements allow clinicians to manage patients with Type 1 diabetes better, they also add complexity to patient treatment. An updated text to address the concepts behind the recognition of new onset Type 1 diabetes in adults, the ongoing care of adults with established Type 1 diabetes, and future potential therapies and devices is warranted to review these issues for both endocrinologists and primary care providers with an interest in diabetes.
As part of the Oxford American Endocrinology Library, this volume stands as a concise guide in the treatment of Type 1 Diabetes in adults. The authors briefly examine the classification and pathophysiology of Type 1 diabetes (including predication and prevention and LADA) and address management (blood glucose monitoring, insulin therapy, and Continuous Subcutaneous Insulin Infusion) and complications (Hyperglycemia, Retinocpathy, Nephropathy, Neuropathy, etc) of the disease. Finally and perhaps most significantly, the authors consider "special situations" associated with Type 1 Diabetes patients, including inpatient treatment, pancreas and inslet transplantation, and how to treat pregnant and depressed patients and patients with eating disorders.

Understanding the importance of nanosciences in diabetes is problematic as some texts can be too technical for the novice. This book uses a reader friendly format suitable not only for practitioners but newcomers as well. It begins with general aspects of nanotechnology and nanomedicine in diabetes. It then discusses glucose and glucose sensors based on functional nanocomposites before moving on to a discussion of insulin and the use of nanoprobes to monitor cell processes in the pancreas. Finally, it explores drugs and other treatments, including second-generation sulfonylurea glipizide loaded biodegradable nanoparticles and nanoparticle-mediated delivery of angiogenic inhibitors in diabetic retinopathy."

Over 20 million people in the United States have diabetes, a metabolic disorder characterized by the body's lack of production or ineffective use of insulin, and the rate is on the rise. Diabetes can cause acute, as well as long-term complications when not properly controlled. Some of the complications may include coma, cardiovascular disease, renal failure, blindness, nerve damage, vascular damage, and poor healing which can lead to amputation. Though there is no cure for either Type I or Type II diabetes, ongoing effort to develop new drug and gene therapies continues. In the meantime, the goals of treatment are disease management, prevention of complications, and improved quality of life. The choice of therapeutics varies by diabetes type and may depend on other significant factors. The selected regimen often includes medication, injection therapy, exercise and change in diet.
Over the past few decades, awareness of the importance of early diagnosis and treatment of diabetes has increased significantly. With approximately one-third of those affected by diabetes unaware of their illness, it is critical to make every effort to identify the disease early in its course. The primary care physician is frequently the first to see patients presenting with pre-diabetes and diabetes symptoms. This highly practical volume is specifically designed for primary care physicians and internists on the frontlines of care. It provides a clinically-focused roadmap to providing optimal care for patients with pre-diabetes and diabetes, from the initial patient visit through testing, goal-setting and follow-up care. It offers up-to-date information on diagnosis and treatment options for all types of diabetes, helping to expedite delivery of appropriate care.
Part of the new Oxford American Endocrinology Library, this concise yet comprehensive guide covers current approaches and new developments in the diagnosis, management and treatment of diabetes, including Type I, Type II, and gestational diabetes, as well as additional notes on pre-diabetes. The text covers new and emerging pharmacotherapies and complementary treatment guidelines, as well as valuable guidance on managing the major complications of diabetes. In addition to diet and exercise tips for patients, the guide also provides strategies and tools for inspiring healthier lifestyles and patient compliance to reach health goals.

This book focuses on precocious puberty, providing a unique continuum of expertise looking at puberty from anthropologic, epidemiologic, clinical, and molecular perspectives. The volume addresses broad pubertal changes in the general population while at the same time providing in depth information about specific disorders of puberty and the latest management changes. In particular, the book is intended for endocrinologists and internists.

This book presents an up-to-date survey of the current scientific understanding of obesity and the metabolic syndrome, as well as an overview of the most significant changes to the field over the past 30 years. The book defines obesity and realistically assesses its prevalence. It further examines and evaluates the success of traditional cognitive behavioral treatment. This volume is a thorough reference for obesity and the metabolic syndrome.

This is a comprehensive and novel text that examines key features that predispose individuals to autoimmune diseases. The first section details the basic mechanism of autoimmunity and examines immunogenetic and environmental factors in autoimmunity. The next section examines autoimmune thyroid disease. The third section takes a look at Type 1 diabetes mellitus. In the final section, authors explain other autoimmune endocrinopathies.

This unique and authoritative book presents an up-to-date overview of the many aspects of energy balance and its relationships to disease processes resulting from excess energy consumption and storage. It provides a comprehensive treatment of important research and clinical aspects of energy metabolism and obesity. It will be a valuable resource for endocrinologists, diabetes specialists, internists and family practitioners.

The growing problem of diabetes presents difficult challenges for sufferers and for those in the healthcare professions, who are in the unenviable position of trying to convince patients to change their lifestyle "for their own good." Handbook of Diabetes Management provides practical knowledge and advice that can help you anticipate the challenges of working with these Patients. What's more, since the knowledge here is evidence-based, you can assure your patients that the guidelines you're presenting to them have been shown to be effective. This guide takes into account the complexity of the disease, the diversity of the populations it affects, and the continued improvement of care systems. It discusses the origins of diabetes and medication management and treatment, then presents advice based on the latest research findings on: -behavioral health and self-management issues and interventions -tips for patients dealing with issues such as travel, surgery, and foot care -treating specific patient populations including Latinos, Native Americans, rural communities, and the uninsured -case studies from successful, replicable programs Also addressing the business aspects of diabetes care related to such areas as legal and regulatory issues and health policy initiatives, Handbook of Diabetes Management, brings you practical insights based on the latest research. "This handbook book by expert professionals covers every aspect of diabetic care. It is a sound, evidence-based, culturally informative, practical approach to diabetes prevention and disease management." -Kathleen Lambert, BSN, RN, JD, from the Foreword

Metabolic Syndrome (MS) is a highly prevalent condition in developed countries and is a cluster of several risk factors for type 2 diabetes and cardiovascular disease that includes increased body mass index/waist circumference, visceral obesity, insulin resistance, hyperclycaemia, dyslipidaemia and hypertension, which are all major causes of morbidity and death. This volume provides a critical review and discussion of the knowledge gathered on MS and analyzes the interplay between oxidative stress, chronic inflammation and angiogenesis features. There is a special focus on recent discoveries and progress toward possible therapeutic strategies, such as the role of glucose transporters within MS; the effects of polyphenols as anti-oxidant, anti-inflammatory and anti-angiogenic compounds. The role of NFkB, nitric oxide synthases, hypoxia-inducible factors, and many other molecules that play a part in the development of oxidative stress and inflammation as well as angiogenesis is also covered. This book fills the gap between basic science and medical care, and provides the reader with the skills to apply rigorous basic science to clinical settings of metabolic syndrome-associated disorders.